VANCOUVER, Aug. 8 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the “Company”) , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that Dr. Gerald Batist, the Director of the McGill Center for Translational Research in Cancer based at the Jewish General Hospital in Montreal, has joined the Company’s Clinical Advisory Board. Comprised of leading oncologists and translational researchers, Chemokine’s Advisory Boards play important roles in guiding and participating in Chemokine’s clinical development programs.
“Dr. Batist’s experience and breadth of knowledge related to the clinical development of novel therapeutic compounds, such as Chemokine’s CTCE-9908 for the prevention of cancer metastasis, is sure to strengthen our Clinical Advisory Board,” stated Dr. Guy Ely, Chief Medical Officer for Chemokine Therapeutics. “Moreover, Dr. Batist’s participation will also serve to enhance our cancer research program currently being conducted with Jewish General Hospital.”
About Gerald Batist, M.D.
Dr. Batist is a Professor and the Chairman of the McGill University Department of Oncology and the Director of the Segal Cancer Centre at the Sir Mortimer B. Davis-Jewish General Hospital, which includes the Montreal Centre for Experimental Therapeutics in Cancer.
Dr. Batist, in the capacity as Chairman of Oncology, has nurtured to development a number of multidisciplinary programs that have been highly innovative and among the first of their kind in Canada. He is a member of a number of scholarly associations, and serves on editorial boards and a number of advisory committees. He also oversees a highly successful laboratory and clinical research program with over 150 scientific publications and a number of book chapters related to his research interests in novel therapeutics. While training a large number of scientists and clinical oncologists, he also maintains an active medical oncology practice.
About the Sir Mortimer Jewish General Hospital
The Jewish General Hospital is an acute-care McGill University teaching hospital with 637 beds, serving patients from Montreal, across the province of Quebec and beyond. Committed to the highest standards of patient care, teaching and research, the JGH has earned a reputation for excellence in many clinical specialties.
A major award from the Canadian Foundation for Innovation led to the expansion of the Translational Research Centre to the Montreal Centre for Experimental Therapeutics in Cancer, which is a major component of the Segal Cancer Centre at the Jewish General Hospital. The Centre provides research and clinical research infrastructure required for the development and testing of novel cancer therapeutics and preventive agents.
Oncologists at the Jewish General Hospital have started administering CTCE-9908 to patients with late stage cancers to evaluate safety and the ability of CTCE-9908 to halt the spread of cancer as part of the ongoing phase Ib/II clinical trial.
About CTCE-9908
CTCE-9908 is an antagonist of Chemokine stromal cell derived factor 1 (SDF-1). The Company has completed a phase I, dose-escalation clinical trial using CTCE-9908 in volunteers, demonstrating CTCE-9908 to be safe and well tolerated by the study subjects. The current phase Ib/II clinical trial that is designed to demonstrate safety as well as to explore early signs of efficacy after repeat administration of CTCE-9908 in a late stage cancer setting was initiated May 2006 with two institutions, the Juravinski Cancer Center in Hamilton and the Jewish General Hospital in Montreal participating as clinical trial sites.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, and stem cells, as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development. For more information, please visit the Company’s website at www.chemokine.net.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “projects”, and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company’s public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT: Elite Financial Communications Group, Chemokine Investor/Media Relations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail: chkt@efcg.net
Chemokine Therapeutics Corp.
CONTACT: Elite Financial Communications Group, Chemokine Investor/MediaRelations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail:chkt@efcg.net
